Neurometrix, Inc. (NASDAQ:NURO) Announces Their Quell Device Will Make a Second Appearance at American Society of Regional Anesthesia’s Annual Pain Medicine Meeting, How Will the Market Respond?

Commercial stage, innovation driven healthcare company combining bioelectrical and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes, Neurometrix, Inc. (NASDAQ:NURO), announces that their newest device will be featured.

WALTHAM, Mass.–(BUSINESS WIRE)–

NeuroMetrix, Inc. (Nasdaq: NURO, NUROW) announced today that Quell® Wearable Pain Relief Technology™ will be featured for the second year in a row at the American Society for Regional Anesthesia’s Annual Pain Medicine Meeting to be held November 17-19 in San Diego, CA.

“Since we introduced Quell to the ASRA community a year ago, we have made significant progress against our healthcare professional strategy,” said Shai N. Gozani, M.D., Ph.D., President and Chief Executive Officer of NeuroMetrix. “In the past 12 months, NeuroMetrix has captured over 2,000,000 hours of user data in the Quell Health Cloud, published results in the Journal of Pain Research, and initiated several clinical evaluations that we are excited to discuss with this year’s meeting attendees.”

About the American Society for Regional Anesthesia (ASRA) and its Annual Pain Medicine Meeting

Originally founded in 1923, ASRA was reborn in 1975 and is the largest subspecialty medical society in anesthesiology. It has approximately 4,000 members, including physicians and scientists, and a rich international distribution. ASRA’s Annual Pain Medicine Meeting will bring together over 1,000 clinical practitioners and researchers in the area of pain medicine. For more information, visit www.asra.com.

About Quell

Quell is designed for millions of people suffering from chronic pain. The advanced wearable device is lightweight and can be worn during the day while active, and at night while sleeping. It has been cleared by the FDA for treatment of chronic pain without a prescription. In a recent study, 81% of Quell users reported an improvement in their chronic pain. Quell users can start, stop, and adjust therapy discreetly via the optional Quell Relief app. Quell also offers advanced sleep tracking that provides feedback on eight dimensions of sleep including sleep duration, quality, body position, time out of bed, and repetitive leg movements throughout the night. Quell was the winner of the 2016 SXSW (South by Southwest) Innovation Award for Best Wearable Technology. Quell is available at select healthcare professionals and retailers. Visit QuellRelief.com for more information.

About NeuroMetrix

NeuroMetrix is a commercial stage, innovation driven healthcare company combining bioelectrical and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The company’s lead product is Quell, an over-the-counter wearable therapeutic device for chronic pain. Quell is integrated into a digital health platform that helps patients optimize their therapy and decrease the impact of chronic pain on their quality of life. The company also markets DPNCheck®, a rapid point-of-care test for diabetic neuropathy, which is the most common long-term complication of Type 2 diabetes. The company maintains an active research effort and has several pipeline programs, including a therapeutic device for restless leg syndrome. The company is located in Waltham, Massachusetts and was founded as a spinoff from the Harvard-MIT Division of Health Sciences and Technology in 1996. For more information, please visit www.NeuroMetrix.com.

Original Source

neurometrix-graph

Shares of Neurometrix, Inc. (NASDAQ:NURO) are actively moving +4.96% thus far today on the news and have traded in the range of $1.18 – 1.38 during the session.  A number of research firms have recently weighed in on the stock, providing future price targets. The covering firms currently have a consensus one-year price target of $4.50 on the stock.  This is according to brokerage analysts polled by Thomson Reuters First Call.  This is the average number from the individual targets provided by the firms.  Analysts are projecting earnings per share of $-0.30 for the next fiscal quarter.  For the current year, analysts are predicting earnings of $-6.39 per share according to First Call.

In looking at where the stock is trading on a technical level, the stock is trading -7.05% away from its 50-day moving average of $1.37.  Based on the most recent available data, the equity is -59.03% off of its 52-week high of $3.10 and +13.39% away from its 52-week low which is $1.12.

Are Shares of Neurometrix, Inc. (NASDAQ:NURO) Ready to Explode?  Sign up to our Newsletter to be the First to Know

Sign up to get our Free Penny Stock Picks Before the Street!

Today, the stock opened at $1.23 and the last bid at the time of writing stood at $1.27.  During the session thus far, the equity dipped down to $1.18 and touched $1.38 as the high point.  Neurometrix, Inc. (NASDAQ:NURO) has a market cap of $6.75M and has seen an average daily volume of 68,320 over the past three months.

Sign Up to Receive Breaking Alerts on Stocks That Are Primed to Make a Run in the Bar Below.

Sign up to get our Free Penny Stock Picks Before the Street!

Disclaimer: The advice provided on this website is general advice only. It has been prepared without taking into account your objectives, financial situation or needs. Before acting on this advice you should consider the appropriateness of the advice, having regard to your own objectives, financial situation and needs.  Where quoted, past performance is not indicative of future performance.

Related posts

Leave a Comment